Abbott Laboratories (NYSE:ABT) Shares Purchased by Nicolet Bankshares Inc.

Nicolet Bankshares Inc. lifted its position in Abbott Laboratories (NYSE:ABT) by 8.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 27,259 shares of the healthcare product maker’s stock after acquiring an additional 2,012 shares during the period. Abbott Laboratories accounts for approximately 0.9% of Nicolet Bankshares Inc.’s investment portfolio, making the stock its 18th biggest holding. Nicolet Bankshares Inc.’s holdings in Abbott Laboratories were worth $2,179,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. Vanguard Group Inc boosted its holdings in Abbott Laboratories by 1.6% in the third quarter. Vanguard Group Inc now owns 139,012,321 shares of the healthcare product maker’s stock valued at $10,197,944,000 after purchasing an additional 2,208,781 shares during the last quarter. BlackRock Inc. boosted its holdings in Abbott Laboratories by 3.3% in the fourth quarter. BlackRock Inc. now owns 121,045,590 shares of the healthcare product maker’s stock valued at $8,755,228,000 after purchasing an additional 3,842,101 shares during the last quarter. Oregon Public Employees Retirement Fund boosted its holdings in Abbott Laboratories by 7,559.6% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 30,095,862 shares of the healthcare product maker’s stock valued at $416,000 after purchasing an additional 29,702,943 shares during the last quarter. Northern Trust Corp boosted its holdings in Abbott Laboratories by 2.7% in the fourth quarter. Northern Trust Corp now owns 26,603,904 shares of the healthcare product maker’s stock valued at $1,924,260,000 after purchasing an additional 708,691 shares during the last quarter. Finally, FMR LLC boosted its stake in shares of Abbott Laboratories by 118.2% during the 4th quarter. FMR LLC now owns 23,762,285 shares of the healthcare product maker’s stock worth $1,718,726,000 after acquiring an additional 12,871,418 shares in the last quarter. 73.35% of the stock is currently owned by institutional investors.

Several equities research analysts have recently issued reports on ABT shares. Barclays set a $84.00 target price on shares of Abbott Laboratories and gave the stock a “buy” rating in a research note on Friday, March 8th. Zacks Investment Research lowered shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, May 8th. Wells Fargo & Co reissued a “buy” rating on shares of Abbott Laboratories in a research note on Thursday, March 14th. Bank of America reaffirmed a “buy” rating and issued a $81.00 price target on shares of Abbott Laboratories in a research note on Thursday, June 13th. Finally, Royal Bank of Canada raised their price target on shares of Abbott Laboratories to $82.00 and gave the company a “buy” rating in a research note on Monday, April 15th. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, four have given a hold rating and fourteen have issued a buy rating to the stock. Abbott Laboratories currently has an average rating of “Buy” and a consensus target price of $81.38.

In other Abbott Laboratories news, SVP Jaime Contreras sold 918 shares of the firm’s stock in a transaction that occurred on Monday, April 22nd. The shares were sold at an average price of $73.12, for a total value of $67,124.16. Following the completion of the transaction, the senior vice president now owns 34,706 shares of the company’s stock, valued at approximately $2,537,702.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Brian J. Blaser sold 450,062 shares of the firm’s stock in a transaction that occurred on Thursday, May 23rd. The shares were sold at an average price of $75.52, for a total transaction of $33,988,682.24. Following the completion of the transaction, the insider now directly owns 295,745 shares of the company’s stock, valued at approximately $22,334,662.40. The disclosure for this sale can be found here. Insiders have sold a total of 1,199,910 shares of company stock valued at $93,837,075 in the last ninety days. 0.70% of the stock is currently owned by corporate insiders.

ABT stock traded up $0.39 during mid-day trading on Monday, reaching $84.49. The company’s stock had a trading volume of 4,514,920 shares, compared to its average volume of 5,835,842. The company’s 50 day moving average price is $79.82. The stock has a market cap of $149.41 billion, a PE ratio of 29.34, a PEG ratio of 2.37 and a beta of 1.10. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.13 and a current ratio of 1.58. Abbott Laboratories has a fifty-two week low of $60.32 and a fifty-two week high of $85.45.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, April 17th. The healthcare product maker reported $0.63 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.61 by $0.02. The business had revenue of $7.54 billion during the quarter, compared to the consensus estimate of $7.49 billion. Abbott Laboratories had a net margin of 8.53% and a return on equity of 16.86%. The business’s revenue was up 2.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.59 EPS. On average, research analysts forecast that Abbott Laboratories will post 3.22 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, August 15th. Investors of record on Monday, July 15th will be given a dividend of $0.32 per share. The ex-dividend date is Friday, July 12th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 1.51%. Abbott Laboratories’s payout ratio is currently 44.44%.

About Abbott Laboratories

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.

Further Reading: What is a put option?

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.